Accumulated doses of vaccine against Covid-19 and Incidence, Lethality and Mortality rates in pregnant and postpartum women by brazilian macroregion. by Marcela de Andrade Pereira Silva (12877870)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”

Parameters used in the simulations. by Yongfeng Zhu (7361045)

Subjects:

The CDF of normal and tangential contact forces in numerical specimens after compression considering different particle morphologies: (a) normal contact force; (b) tangential conta... by Yongfeng Zhu (7361045)

Subjects:

Two ellipsoidal particles in contact. by Yongfeng Zhu (7361045)

Subjects:

The normal force between two particles with different equivalent diameters for P3: (a) hertznormal contact force; (b) normal viscous contact force. by Yongfeng Zhu (7361045)

Subjects:

Different ellipsoidal particles with De = 6.30 mm used in the discrete element simulations. by Yongfeng Zhu (7361045)

Subjects:

Comparative analysis of the proposed modified contact model against previous approaches. by Yongfeng Zhu (7361045)

Subjects:

Deviatoric stress-strain curves of numerical samples composed of elongated ellipsoids with different particle morphologies and particle sizes. by Yongfeng Zhu (7361045)

Subjects:

Different contact patterns for two ellipsoids. by Yongfeng Zhu (7361045)

Subjects:

The normal force between two particles with De = 6.30 mm for different aspect ratios and sphericities: (a) hertz normal contact force; (b) normal viscous contact force. by Yongfeng Zhu (7361045)

Subjects:

The force chain distributions of different numerical samples composed of elongated ellipsoids with different particle morphologies and particle sizes before shearing and after load... by Yongfeng Zhu (7361045)

Subjects:

The tangential force between two particles with different aspect ratios and sphericities for De = 6.30 mm: (a) elastic tangential contact force; (b) viscous tangential contact forc... by Yongfeng Zhu (7361045)

Subjects:

Critical state parameters obtained from DEM simulations. by Yongfeng Zhu (7361045)

Subjects:

The tangential force between two particles with different equivalent diameters for P3: (a) elastic tangential contact force; (b) viscous tangential contact force. by Yongfeng Zhu (7361045)

Subjects:

ITSA regression results of weekly total cost and cost components per capita for inpatients in the non-surgical group before and after DIP payment intervention. by Chenxuan Zhu (22622476)

Subjects: